Anika Therapeutics, Inc. Fair Value Disclosure
4. Fair Value Measurements
There were available-for-sale securities as of December 31, 2025 and 2024.
The Company’s investments, including cash equivalents, are all classified within Levels 1 of the fair value hierarchy and are valued based on quoted prices in active markets. For cash, accounts receivable, accounts payable, and accrued interest, the carrying amounts approximate fair value, because of the short maturity of these instruments, and therefore fair value information is not included in the table below.
The classification of the Company’s cash equivalents and investments within the fair value hierarchy is as follows:
|
Active Markets |
Significant Other |
Significant |
||||||||||||||||||
|
for Identical Assets |
Observable Inputs |
Unobservable Inputs |
||||||||||||||||||
|
December 31, 2025 |
(Level 1) |
(Level 2) |
(Level 3) |
Amortized Cost |
||||||||||||||||
|
Cash equivalents: |
||||||||||||||||||||
|
Money Market Funds |
$ | 48,758 | $ | 48,758 | $ | - | $ | - | $ | 48,758 | ||||||||||
|
Active Markets |
Significant Other |
Significant |
||||||||||||||||||
|
for Identical Assets |
Observable Inputs |
Unobservable Inputs |
||||||||||||||||||
|
December 31, 2024 |
(Level 1) |
(Level 2) |
(Level 3) |
Amortized Cost |
||||||||||||||||
|
Cash equivalents: |
||||||||||||||||||||
|
Money Market Funds |
$ | 46,061 | $ | 46,061 | $ | - | $ | - | $ | 46,061 | ||||||||||
There were no transfers between fair value levels during the years ended December 31, 2025 and 2024, respectively.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 3, 2026 | Showing above |
| 2024 | Mar 17, 2025 | |
| 2023 | Mar 15, 2024 | |
| 2022 | Mar 16, 2023 | |
| 2021 | Mar 11, 2022 | |
| 2020 | Mar 5, 2021 | |
About Fair Value Disclosures
Fair value disclosures classify all assets and liabilities measured at fair value into a three-level hierarchy: Level 1 (quoted market prices), Level 2 (observable inputs like yield curves), and Level 3 (unobservable inputs requiring management estimates). The proportion of Level 3 assets directly reflects how much of the balance sheet depends on internal models rather than market evidence.
Key signals: a growing Level 3 balance relative to total fair-value assets increases valuation uncertainty and earnings volatility risk. Watch for transfers between levels — assets moving from Level 2 to Level 3 often signal deteriorating market liquidity. Unrealized gains and losses on Level 3 positions flow through earnings or other comprehensive income, so large swings deserve scrutiny. For financial institutions, examine the sensitivity disclosures that show how Level 3 valuations change under alternative assumptions. Compare the fair value of debt against its carrying amount to gauge hidden leverage.